| P50 | author | Jane Worthington | Q29998784 |
| | Anne Barton | Q30348373 |
| | Wendy Thomson | Q42653464 |
| | Tracey Farragher | Q47524777 |
| | Deborah P.M. Symmons | Q54100237 |
| | Paul Martin | Q54165701 |
| | Stephen Eyre | Q55188147 |
| P2093 | author name string | E Flynn | |
| | D Bunn | |
| | D Plant | |
| P2860 | cites work | De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling | Q24299573 |
| | TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study | Q24657292 |
| | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| | A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis | Q28267921 |
| | The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis | Q28306666 |
| | Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis | Q28375106 |
| | An evaluation of the decision tree format of the American College of Rheumatology 1987 classification criteria for rheumatoid arthritis: Performance over five years in a primary care-based prospective study | Q57804956 |
| | A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis | Q33299576 |
| | STAT4: genetics, mechanisms, and implications for autoimmunity | Q34804543 |
| | Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis | Q36463121 |
| | Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility | Q36769297 |
| | Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. | Q36802977 |
| | Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? | Q37000103 |
| | Recent advances in the genetics of RA susceptibility | Q37080741 |
| | CD226 Gly307Ser association with multiple autoimmune diseases | Q37083069 |
| | Two independent alleles at 6q23 associated with risk of rheumatoid arthritis | Q37120830 |
| | Rheumatoid arthritis association at 6q23. | Q37172071 |
| | Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes | Q37223270 |
| | Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. | Q37239881 |
| | Rheumatoid arthritis: a view of the current genetic landscape | Q37315484 |
| | Common variants at CD40 and other loci confer risk of rheumatoid arthritis | Q37376871 |
| | Pharmacogenetics of warfarin | Q37580929 |
| | Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation | Q38297721 |
| | Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. | Q40338460 |
| | Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis | Q42491562 |
| | Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases | Q43089300 |
| | Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. | Q43154311 |
| | Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study | Q43771027 |
| | Susceptibility variants for rheumatoid arthritis in the TRAF1-C5 and 6q23 loci: a meta-analysis | Q43949763 |
| | Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis | Q44210170 |
| | Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment | Q46242303 |
| | A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis | Q57788757 |
| P433 | issue | 2 | |
| P921 | main subject | methotrexate | Q422232 |
| P304 | page(s) | 128-133 | |
| P577 | publication date | 2010-10-05 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register | |
| P478 | volume | 12 | |